The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

BOCA RATON, Fla. (AP) — BOCA RATON, Fla. (AP) — ADT Inc. (ADT) on Monday reported fourth-quarter net income of $145 million. The Boca Raton, Florida-based company said it had net income of 17 cents ...

ADT on Tuesday announced an interesting new acquisition for anyone looking to the future of home security-- and it's no surprise AI is a part of the story. In a $170 million deal, ADT has purchased ...

BOCA RATON, Fla. — ADT, a provider of smart home solutions serving residential and small business customers in the U.S., has announced that it has acquired Origin Wireless, Inc. (d/b/a “Origin AI” and ...

ADT (Nasdaq: ADT) has acquired Origin Wireless, bringing the company’s AI sensing platform and related intellectual property into the ADT ecosystem in a move aimed at advancing intelligent home ...

The company will use Origin Wireless’ AI sensing to expand the capabilities of its smart home security products. The company will use Origin Wireless’ AI sensing to expand the capabilities of its ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

ADT is a defensive, cash-generative business trading below intrinsic value, assuming it increases its ROIC. State Farm and Apollo, holding ~27% combined, may sell shares, potentially pressuring ADT’s ...

ADT delivered solid Q3 performance with higher earnings, cash flow and installation revenue driven by ADT+. Attrition ticked up, but management expects improvement in early 2026 as customer experience ...

Androgen deprivation therapy (ADT), also called hormone therapy, is a common treatment for metastatic prostate cancer. It works by starving the cancer of testosterone, which fuels the tumor’s growth.